With Illinois COVID-19 Cases Soaring, Officially Reported Information Is Increasingly Useless
RNA structures of coronavirus reveal potential drug targets
Respirator 2.0: new n95-alternative introduces sensors for a better fit
Plasma treatments quickly kill coronavirus on surfaces
News briefing: Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia
U.S. has plan to start Pfizer vaccine shots in December: CNBC
Pharma’s response to COVID-19: Lilly and diabetes care
Lilly to ship COVID-19 drug straight away after FDA green light
Pharma’s response to COVID: Lilly and diabetes care
Eli Lilly’s Covid-19 Antibody Treatment Gets FDA Emergency Use Nod
Scabies: the neglected tropical disease no one wants to talk about
After NICE okay, Scots denied access to Vifor’s Veltassa
It’s just a jump to the left
U.S. allows emergency use of first Covid-19 antibody drug
Good Entry Point for Amarin Stock? Not Just Yet, Says Analyst
5 Things Patient Advocates Want Pharma and the Healthcare Industry to Know
Biogen plunges 30% after FDA panel votes against Alzheimer’s drug
Top UK Scientists Warn "Many, Or All" COVID-19 Vaccine Projects Could Fail, First Gen "Likely To Be Imperfect"
Ocular Therapeutix Rises 7% On Stellar Results Backed By Dextenza
Digital therapies for opioid use disorder need more data, says ICER
This recession, banks are the good guys
German Doctors Urge Chancellor Merkel: Put An End To The COVID "Fear Machine"
Biden Taps BARDA Whistleblower Rick Bright for Covid-19 Advisory Board
Combative U.S. FDA panel votes against Biogen Alzheimer’s drug
AstraZeneca’s Heart Drug Gets FDA Nod For Stroke Reduction Use
Expert panel review on Alzheimer’s drug aducanumab becomes a one-day trial by fire as critics turn their guns on Biogen — and the FDA
Expert panel review on the Alzheimer’s drug aducanumab turns into a one-day trial by fire as critics turn their guns on Biogen — and the FDA
U.S. FDA panel votes successful study on Biogen Alzheimer’s drug cannot stand alone
Bharat Biotech – COVAXIN™
Study reveals strategy to create COVID-19 drugs to inhibit virus’s entry and replication